☆ 4.7 Article

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis

JOURNAL OF AFFECTIVE DISORDERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder

Joshua Liberman et al.

Summary: This study aimed to determine if social determinants of health and distance were associated with the utilization of esketamine (ESK) for treatment-resistant depression or major depression with suicidal ideation. The findings showed that population density, ethnicity, and the number of mental health and primary care providers per capita were associated with ESK initiation, while living far from a treatment center, residing in rural areas, and higher proportions of non-Hispanic African American and Hispanic populations were associated with lower likelihood of ESK initiation. Healthcare providers should tailor patient engagement strategies to address potential barriers to initiating and continuing appropriate treatment. Failure to complete induction was associated with substance use disorder and longer distance to treatment center, while higher proportions of Asian population were associated with treatment discontinuation. Prior psychiatric care and residence in counties with high rates of primary care providers per capita, unemployment, and high school graduation were associated with both higher likelihood of completing induction and lower likelihood of discontinuation.

MEDICINE (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Long-term safety of ketamine and esketamine in treatment of depression

Sina Nikayin et al.

Summary: Ketamine and esketamine have generally transient, mild, and self-limited side effects. The use of esketamine could increase the risk of lower urinary tract symptoms, but severe bladder pathology has not been reported at recommended doses. High doses of ketamine may lead to long-term impairments in cognition, but esketamine clinical trials suggest that cognition remains stable or improves over time when used appropriately.

EXPERT OPINION ON DRUG SAFETY (2022)

添加到收藏夹

Article Clinical Neurology

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings

L. Alison McInnes et al.

Summary: This study examined the treatment response of depression patients receiving KIT in community practices. The results showed that more than half of the patients exhibited a treatment response after induction, and approximately one-third achieved remission. KIT has a significant antidepressant effect, but a small percentage of patients experienced worsening symptoms.

JOURNAL OF AFFECTIVE DISORDERS (2022)

添加到收藏夹

Review Psychiatry

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis

Yazen Alnefeesi et al.

Summary: Ketamine shows promising clinical effectiveness in the treatment of treatment-resistant depression (TRD), as demonstrated by a systematic review and meta-analysis. The study findings indicate a substantial mean antidepressant effect, with potential benefits for even the most treatment-resistant patients.

JOURNAL OF PSYCHIATRIC RESEARCH (2022)

添加到收藏夹

Review Neurosciences

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials

Jacob S. Aday et al.

Summary: Psychedelic research is gaining significant interest, but faces challenges such as expectancy effects and effective condition masking, which may limit interpretability of results. Recommendations for improving research rigor include enhancing masking procedures and reducing participant expectancies.

PSYCHOPHARMACOLOGY (2022)

添加到收藏夹

Article Psychiatry

Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study

Sachin Ahuja et al.

Summary: This study aimed to evaluate the clinical characteristics, treatment patterns, clinical outcomes, and adverse events of patients receiving intramuscular (IM) ketamine treatment at an outpatient psychiatric clinic. The results showed significant improvements in depression and anxiety scores throughout the course of IM ketamine treatment, which were maintained during the maintenance treatment phase. Adverse events were rare.

BMC PSYCHIATRY (2022)

添加到收藏夹

Article Clinical Neurology

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial

Thomas D. Hull et al.

Summary: At-home Ketamine-assisted therapy with psychosocial support and remote monitoring has shown significant improvement in treating depression and anxiety. The response and remission rates are consistent with laboratory- and clinic-administered ketamine treatment, and adverse events are minimal.

JOURNAL OF AFFECTIVE DISORDERS (2022)

添加到收藏夹

Article Psychiatry

Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use

Kazi Hassan et al.

Summary: This study assessed the effectiveness and safety of self-administration of off-label, sublingual, rapid dissolve ketamine tablets at-home for depression and anxiety. The results showed that sublingual ketamine is a novel, safe, and effective treatment for treatment-resistant depression and anxiety.

FRONTIERS IN PSYCHIATRY (2022)

添加到收藏夹

Article Psychology, Clinical

Clinical Effectiveness 01 intravenous Racemic etamineTnr Bions in a Large Community Sample of Patients With Treatment- Resistant Depression, Suicidal Ideation, and Generalized

Patrick A. Oliver et al.

Summary: This study examines the clinical outcomes of ketamine treatment for patients with treatment-resistant depression (TRD). The results show that ketamine is effective in reducing suicidal ideation, depression, and anxiety symptoms. Within 6 weeks, 50% of patients showed a response to the treatment and 20% achieved remission of depressive symptoms. After 10 infusions, response and remission rates increased to 72% and 38% respectively. Moreover, there was a significant reduction in suicidal ideation symptoms after 6 infusions. The efficacy of ketamine is comparable to other interventions for TRD in community samples.

JOURNAL OF CLINICAL PSYCHIATRY (2022)

添加到收藏夹

Article Psychiatry

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

Roger S. McIntyre et al.

Summary: Replicated international studies have highlighted the human and societal costs of major depressive disorder, with monoamine-based antidepressants proving effective but many patients failing to fully recover. Ketamine and esketamine offer novel pharmacological treatments for treatment-resistant depression, but questions remain about their safety and effectiveness. International experts provide guidance on the use of these agents, while discussing areas of consensus and future research directions.

AMERICAN JOURNAL OF PSYCHIATRY (2021)

添加到收藏夹

Article Clinical Neurology

The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder

Roger S. McIntyre et al.

BIPOLAR DISORDERS (2020)

添加到收藏夹

Article Clinical Neurology

The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence

Roger S. McIntyre et al.

JOURNAL OF AFFECTIVE DISORDERS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials

Joanna Kryst et al.

PHARMACOLOGICAL REPORTS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence

Nelson B. Rodrigues et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Article Clinical Neurology

Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder

Wei Zheng et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2019)

添加到收藏夹

Article Psychology, Clinical

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression

Naji C. Salloum et al.

DEPRESSION AND ANXIETY (2019)

添加到收藏夹

Article Psychiatry

Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial

Jennifer L. Phillips et al.

AMERICAN JOURNAL OF PSYCHIATRY (2019)

添加到收藏夹

Article Psychiatry

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis

Samuel T. Wilkinson et al.

AMERICAN JOURNAL OF PSYCHIATRY (2018)

添加到收藏夹

Article Psychology, Clinical

Trajectories of Acute Antidepressant Efficacy: How Long to Wait for Response? A Systematic Review and Meta-Analysis of Long-Term, Placebo-Controlled Acute Treatment Trials

Jonathan Henssler et al.

JOURNAL OF CLINICAL PSYCHIATRY (2018)

添加到收藏夹

Article Psychiatry

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression

Jaskaran B. Singh et al.

AMERICAN JOURNAL OF PSYCHIATRY (2016)

添加到收藏夹

Article Clinical Neurology

A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

Dawn F. Ionescu et al.

BIPOLAR DISORDERS (2015)

添加到收藏夹

Article Psychiatry

Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety

Elizabeth D. Ballard et al.

JOURNAL OF PSYCHIATRIC RESEARCH (2014)

添加到收藏夹

Article Neurosciences

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

James W. Murrough et al.

BIOLOGICAL PSYCHIATRY (2013)

添加到收藏夹

Article Medicine, Research & Experimental

International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol

Leanne M. Williams et al.

TRIALS (2011)

添加到收藏夹

Article Psychiatry

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report

Maurizio Fava et al.

AMERICAN JOURNAL OF PSYCHIATRY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.